Oppenheimer Sticks to Its Buy Rating for Durect (DRRX)
Oppenheimer analyst Francois Brisebois reiterated a Buy rating on Durect (DRRX – Research Report) on March 27 and set a price target of $5.00.
Sensei Biotherapeutics (SNSE) Gets a Buy from Oppenheimer
In a report released on March 28, Francois Brisebois from Oppenheimer maintained a Buy rating on Sensei Biotherapeutics (SNSE – Research ...
Q4 2024 DURECT Corp Earnings Call
Timothy Papp; Chief Financial Officer; DURECT Corp. James Brown; President, Chief Executive Officer, Director; DURECT Corp. Norman Sussman; Chief Medical Officer; DU ...
DURECT Corporation (NASDAQ:DRRX) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter and Full Year 2024 Earnings Conference Call. At ...
DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis
Discover DURECT's Q4 2024 earnings insights, progress on larsucosterol's Phase 3 trial for alcohol-associated hepatitis, and strategies to secure funding.
Seeking Alpha5d
DURECT outlines $20M Phase 3 trial for larsucosterol in alcohol-associated hepatitis
François Brisebois, Oppenheimer & Company: Asked about the estimated cost of the Phase 3 trial. CEO Brown stated it would be around $20 million, with potential for slight cost reductions.
Le Journal de Montréal3d
Marie-France Bornais
Une relation complexe marquée par la dépendance Marianne Brisebois explore les hauts et les bas d’une relation marquée par la dépendance dans son nouveau roman, «Fragments d’Olivier».